[Clinical observations on the therapeutic activity of the preparation mendiaxon in diseases of the biliary tract].
The immediate effect of 400 mg mendiaxon was studied in 8 patients with various hepatobiliary diseases. The drug was administered via a duodenal tube in a duodenal drainage tubing according to a minute schedule during the phase of pure bile C secretion. An increased volume was found in all cases. The maximum choleresis exceeds the basal one from 3 to 8 times. The rate of bile flow, in the majority of the patients, was between 2 and 3.3. ml/min. The treatment was carried out on 25 patients in the course of 10 days with a daily dose of 1200 mg (400 mg three times). A good pain-killing effect was obtained. Adverse effects and allergic reactions were not observed. The results from our studies provided grounds to recommend mendiaxon use in the clinical practice.
D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002756:Cholagogues and Choleretics; D002763:Cholecystectomy; D002764:Cholecystitis / Q000188:drug therapy; D002769:Cholelithiasis / Q000188:drug therapy; D005260:Female; D006801:Humans; D006923:Hymecromone / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics; D011183:Postoperative Complications / Q000188:drug therapy; D013577:Syndrome; D014468:Umbelliferones / Q000627:therapeutic use*
D002756:Cholagogues and Choleretics; D010276:Parasympatholytics; D014468:Umbelliferones; D006923:Hymecromone
Klinichni nabliudeniia vurkhu terapevtichnata aktivnost na preparata mendiakson pri zaboliavaniia na zhluchnite putishta.